Mutations of p53 and K-ras correlate TF expression in human colorectal carcinomas: TF downregulation as a marker of poor prognosis
Tóm tắt
Tissue factor (TF) is emphasized as the promising target in the future targeted therapy strategy for colorectal cancer (CRC). Recent evidence showed that TF expression is under the control of K-ras and p53. However, a comprehensive evaluation of TF expression, K-ras status, and p53 mutation has not been systematically analyzed. The aims of this study were to identify the percentages of positive TF in CRC patients; analyze the associations of TF expression, K-ras status, and p53 mutation; and evaluate the prognostic value of TF in CRC patients. Ninety-six CRC samples were tested for TF expression, p53 mutation, and K-ras status by semiquantitative immunohistochemistry, Western blotting analysis, direct sequencing, and real-time quantitative PCR. Associations were sought with TF expression and clinical outcomes. TF expression was related to clinical stages, tumor differentiation, and tumor size. The positive proportions of TF expression on tumor cells and tumor vascular endothelial cells were 70% and 53% respectively in CRC patients. The positive proportion of TF co-expression on both cancer cells and tumor vascular endothelial cells was 40%, compared to an 83% total TF positive proportion in CRC patients. TF expression on CRC appeared to be increased with K-ras and/or p53 mutation(s). Disease-free survival and overall survival were significantly reduced in CRC patients with high TF expression. TF may participate in both K-ras and p53 mutations involved in colorectal carcinogenesis and could be considered as a prognostic indicator for patients CRC.
Từ khóa
Tài liệu tham khảo
Buller HR, van Doormaal FF, van Sluis GL et al (2007) Cancer and thrombosis: from molecular mechanisms to clinical presentations. J Thromb Haemost 5:246–254
Rak J, Milsom C, Yu J (2008) Tissue factor in cancer. Curr Opin Hematol 15:522–528
Chen J, Bierhaus A, Schiekofer S et al (2001) Tissue factor—a receptor involved in the control of cellular properties, including angiogenesis. Thromb Haemost 86:334–345
Rickles FR (2006) Mechanisms of cancer-induced thrombosis in cancer. Pathophysiol Haemost Thromb 35:103–110
Falanga A (2005) Thrombophilia in cancer. Semin Thromb Hemost 31:104–110
Giesen PL, Rauch U, Bohrmann B et al (1999) Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA 96:2311–2315
Mackman N (2008) Triggers, targets and treatments for thrombosis. Nature 451:914–918
Tesselaar ME, Romijn FP, van der Linden IK et al (2007) Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost 5:520–527
Khorana AA, Francis CW, Menzies KE et al (2008) Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost 6:1983–1985
Kakkar AK, DeRuvo N, Chinswangwatanakul V et al (1995) Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor. Lancet 346:1004–1005
Seto Shin-ichi, Onodera H, Kaido T et al (2000) Tissue factor expression in human colorectal carcinoma: correlation with hepatic metastasis and impact on prognosis. Cancer 8(2):295–301
Shigemori C, Wade H, Matsumoto K et al (1998) Tissue factor expression and metastatic potential of CRC. Thromb Haemost 80(6):894–898
Statom CA, Chetwood AS, Cameron IC et al (2007) The angiogenic switch occurs at the adenoma stage I the adenoma–carcinoma sequence in CRC. Gut 12l(13):213–220
Nakasaki T, Wada H, Shigemori C et al (2002) Expression of tissue factor and vascular endothelial growth factor is associated with angiogenesis in CRC. Am J Hematol 69(40):247–254
Lykke J, Nielsen HJ (2004) Haemostatic alterations in CRC: perspectives for future treatment. J Surg Omcol 88(4):269–275
Yu JL, May L, Lhotak V et al (2005) Oncogenic events regulate tissue factor expression in CRC cells: implications for tumor progression and angiogenesis. Blood 105(4):1734–1741
Sierko E, Wojtukiewicz MZ et al (2010) Expression of tissue factor pathway inhibitor (TFPI) in human breast and colon cancer tissue. Thromb Haemost 103:198–204
Hu Z, Garen A (2000) Intratumoral injection of adenoviral vectors encoding tumor-targeted immunoconjugated for cancer immunotherapy in mouse models of prostatic cancer. Proc Natl Acad Sci USA 97(16):9221–9225
Francis JL, Amirkhosravi A (2002) Effect of antihemostatic agents on experimental tumor dissemination. Semin Thromb Hemost 28(1):29–38
Nilsson F, Kosmehl H, Zardi L, Neri D (2001) Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesisi, mediates the infarction of solid tumors in mice. Cancer Res 61:711–716
Jass JR (2006) CRC: a multipathway disease. Crit Rev Oncogenesis 12:273–287
Anwar S, Frayling IM, Scott NA et al (2004) Systematic review of genetic influences on the prognosis of CRC. Br J Surg 91:1275–1291
Sameer AS, Pandith AS, Syeed N et al (2009) Molecular gate keepers succumb to gene aberrations in CRC in Kashmiri population, revealing a high incidence area. Saudi J Gastroenterol 15:244–252
Smith G, Bounds R, Wolf H et al (2010) Activating K-Ras mutations outwith ‘hotspot’ codons in sporadic colorectal tumours—implications for personalised cancer medicine. Br J Cancer 102(4):693–703
Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61:759–767
Mir MM, Dar NA, Gochhait S et al (2005) p53 mutation profile of squamous cell carcinomas of the esophagus in Kashmir (India): a high-incidence area. Int J Cancer 116:62–68
Al-Kuraya KS (2009) K-RAS and TP53 mutations in colorectal carcinoma. Saudi J Gastroenterol 15(4):217–219
Cho YB, Chun HK, Yun HR et al (2009) Histological grade predicts survival time associated with recurrence after resection for CRC. Hepatogastroenterology 56(94–95):1335–1340
Desolneux G, Burtin P, Lermite E et al. (2011) Prognostic factors in node-negative CRC: a retrospective study from a prospective database. Int J Colorectal Dis (in press)